that a mutation at 5'UTR region of TLR2 gene could be associated with susceptibility/resistance to SLE and malaria. We performed a hospital based case-control study on SLE patients residing in *P. falciparum* endemic areas.

**Methods**

Two hundred female SLE patients and age and sex matched healthy controls were enrolled. 120 *P. falciparum* infected patients including 50 uncomplicated cases and 70 severe malarial patients were included. TLR2 (23bp ins/del) polymorphism was typed by polymerase chain reaction (PCR). 20% samples were randomly sequenced for validation of PCR results.

**Results**

The mean age and disease duration of SLE patients were 27.44 and 2.91 years respectively. Prevalence of mutants (ins/del+del/del) of TLR2 gene polymorphism were significantly lower in SLE patients compared to healthy controls (p=0.02; OR=0.54). Distribution of TLR2 variants were comparable among different clinical phenotypes of SLE. The TLR2 5'UTR mutants were associated with elevated TNF alpha, IL1 beta and IL6 compared to the wild genotypes. Mutants were more prevalent in severe malaria patients than uncomplicated cases (p=0.05; OR=2.31).

**Conclusions**

TLR2 5'UTR 23bp ins/del variants are associated with development of severe disease in *P. falciparum* malaria but possibly an evolutionary mechanism to protect SLE patients against severe malaria in endemic areas.
flow cytometry, in relation to clinical parameters and previously established LN classes assessed according to the ISN/RPS 2003 classification.

Results Lymphocytes percentages in class IV were different from classes III, V or a combination of III and V. In the latter classes, the percentages of the Tregs and Th17 cells were significantly lower, whereas in class IV the increase in FOXP3 in the Tregs and Th17 cells over six months period was significantly higher (Table 1). Changes in glomerular filtration rate and SLEDAI within 5 years did not correlate with single or repeated Tregs measurements.

Conclusions Differences in lymphocyte proportions between class IV and other classes may suggest its distinct pathogenesis and warrants further investigations on their role as LN biomarker.

272 CLINICAL SIGNIFICANCE OF ANTI-DNA/NR2 ANTIBODIES IN DE NOVO NPSLE AND POST-STEROID NPSLE

Y Fujieda*, Z Mader, Y Jegnathan, Y Arimuna, M Kato, K Oku, T Bohgaki, O Amengual, Y Sudaba, B Diamond, T Atsumi. Hokkaido University Graduate School of Medicine, Division of Rheumatology-Endocrinology and Nephrology, Sapporo, Japan; The Feinstein Institute for Medical Research, Centre of Autoimmune and Musculoskeletal Diseases, New York, USA

Background and aims Anti-DNA/NR2 antibodies are a subset of anti DNA autoantibodies that cross-react with the extracellular domain of the GluN2A/GluN2B subunits of the N-methyl-d-aspartate receptor 2 (NR2), which induce apoptosis of hippocampus neurons and psychiatric disorder in mice and humans. Neuropsychiatric SLE (NPSLE) can develop after initiation of steroid (post-steroid neuropsychiatric manifestation: PSNP) or before treatment (de novo NPSLE). The objective of this study was to clarify the prevalence of anti-DNA/NR2 antibodies in PSNP-SLE and de novo NPSLE.

Methods This study involved a cohort of patients with NPSLE who were admitted to Hokkaido University Hospital. NPSLE patients were classified into two groups, de novo NPSLE and PSNP-SLE. Serum anti-DNA antibodies and anti-DNA/NR2 antibodies were measured in-house ELISAs.

Results Serum samples were obtained from 29 patients with de novo NPSLE, 26 with PSNP-SLE and 83 healthy controls (HC). The levels of anti-DNA antibodies in patients with de novo NPSLE and PSNP-SLE were significantly higher than those in healthy controls (de novo NPSLE, PSNP-SLE, HC: 1.34±0.09, 1.40±0.14, 0.33±0.03, p<0.0001). The levels of anti-DNA/NR2 antibodies were highest in de novo NPSLE and in PSNP-SLE and HC (de novo NPSLE, PSNP-SLE, HC: 0.75±0.10, 0.60±0.07, 0.49±0.03). In PSNP-SLE, the frequency of mood disorders was higher than that in de novo NPSLE (58% vs 31% p<0.05).

Conclusions The levels of anti-DNA/NR2 in PSNP-SLE are lower than in de novo NPSLE, indicating the differences in the pathogenesis of these two conditions.

273 URINARY TWEAK LEVELS AS BIOMARKER OF LUPUS NEPHRITIS IN COLOMBIAN SLE PATIENTS

BL Ortiz Reyes, T Urrego, AL Vanegas, G Acoc, ACB Bonfanti, L Almedrales, CH Muñoz, AG González, AG Iglesias, GV Vázquez, AG Gómez-Puerta*, Universidad de Antioquia, Grupo de Inmunología celular e Inmunogenética GICIC, Medellín, Colombia; Universidad de Antioquia, Grupo de Reumatología, Medellín, Colombia; Hospital San Vicente Fundación, Reumatología, Medellín, Colombia; Universidad Simon Bolívar, Grupo investigación Nefrología, Barranquilla, Colombia; Universidad Nacional de Colombia, Facultad de Medicina, Bogotá, Colombia

Background and aims TNF-like WEAK inducer of apoptosis (TWEAK), a TNF ligand superfamily is mainly produced by monocytes/macrophages, and is widely expressed at the RNA level in tissues including kidneys. The usefulness of urinary TWEAK (uTWEAK) to identify renal involvement in Mestizo and African-Latin American (ALA) SLE patients has not been examined yet.

Methods Patients meeting the revised ACR criteria for SLE were recruited from 2 different centres at Medellín and Barranquilla, Colombia. uTWEAK were measured using an ELISA kit (R and D system, USA).

Results 158 SLE patients were recruited (89% female) with median age of 32.8±12.1 years and median disease duration of 7.27±6.6 years. Mestizo (77%) and ALA (20%) were majority. 64% of patients had lupus nephritis (LN). 50 out of 71 biopsy proven LN had proliferative forms. Mean SLEDAI score was 8.5±8.7. LN patients (2803±6086 vs 672±1042, p=0.013) (Fig 1A) and ALA patients (3995±9656 vs 1618±2653, p=0.002) had significant higher levels of uTWEAK. uTWEAK levels were higher in patients with active LN and in class V LN (Fig. 1B). uTWEAK levels were significantly correlated with 24 hours proteinuria, SLEDAI (Fig. 1C) and serum anti-C1q titers. An ROC curve constructed showed a good level of sensitivity and specificity (Fig. 1D).

Conclusions In our cohort of Colombian SLE patients, uTWEAK levels were 4 and 2 times higher in LN patients and ALA respectively. uTWEAK were significantly higher in active LN and were correlated with disease activity, proteinuria and anti-C1q antibodies.